<0.001 EU per 1 μg of the protein by the LAL method
The product is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.
Examples of Clinical Use:
Symptomatic vitreomacular adhesion
Mechanism of action:
Ocriplasmin has proteolytic activity against protein components of the vitreous body and the vitreoretinal interface (VRI) (e.g. laminin, fibronectin and collagen), thereby dissolving the protein matrix responsible for the vitreomacular adhesion (VMA).
Ocriplasmin is a recombinant truncated human plasmin protein drug, also known as recombinant truncated human plasmin, It is used to treat Macular cleavage syndrome (Macular Hole) and Vitreomacular Adhesion of the retina. Ocriplasmin works by dissolving adhesive or fibrous attachments in the retina to promote closure of the retinal fissure and retinal disadhesion. It is able to cut the fiber connections in the proteins, thus unbinding the retina tightly. Ocriplasmin is usually administered in the eye as a local injection through a syringe, and the doctor will decide how and how much to use the drug based on the patient's specific conditions, such as the severity of macular lysis syndrome and periretinal adhesions. Although Ocriplasmin is an effective treatment, some side effects can occur, including visual disturbance, eye pain, increased eye pressure, etc., so before using Ocriplasmin, the doctor will conduct a thorough evaluation of the patient and explain its risks and benefits in detail.
2. Clinical application
Ocriplasmin is a recombinant human fibrinolytic enzyme (plasmin) that is used to treat Macular cleavage syndrome (Macular Hole) and Vitreomacular Adhesion. In clinical application, Ocriplasmin is used by local injection into the eye, which can cut the fiber connection in the retina, promote the closure of macular lysis syndrome， and the separation of the retina from the retinal epithelium. For periretinal adhesions, Ocriplasmin unbinds the adhesion between the retina and the vitreous body, thereby restoring normal anatomy. The use of Ocriplasmin is usually done before and after eye surgery performed by a professional physician to improve surgical outcomes and prognosis. It reduces the risk of surgery requiring complete removal of the macula of the retina and provides a non-surgical treatment option. However, there are some limitations to the clinical application of Ocriplasmin. The response of different patients to the drug may vary, and the effectiveness of treatment is not 100% guaranteed. Some patients may need further manipulation or other treatments to achieve the best results. When using Ocriplasmin, the doctor will develop an individualized treatment plan based on the patient's assessment and specific circumstances; In the course of use, patients need to closely cooperate with the doctor's guidance, and receive regular review and monitoring after treatment. Overall, Ocriplasmin is clinically used for the treatment of macular lysis syndrome and periretinal adhesions, providing a non-surgical treatment option. However, please note that the specific use and effects need to be determined based on the evaluation and recommendation of the doctor.
3. Mechanism of action
Specifically, Ocriplasmin is a protease that degrades or oxygenates retinal tissue with cellulosic properties, removing obstructions and disengaging adhesion. When Ocriplasmin is injected into the eye, it rapidly penetrates into the interface between the retina and the vitreous body, severing the adhesion in the retina, promoting the closure of the macular lysis syndrome and the separation of the retina from the retinal epithelium. For periretinal adhesions, Ocriplasmin is able to cut the adhesion between the retina and the vitreous body, restoring normal anatomy. In addition, Ocriplasmin can also help increase the rate of vitreous liquefaction and eliminate cellulose and collagen fibers within the vitreous mass, thereby promoting the dissolution of adhesion between the retina and the vitreous and the recovery of macular lysis syndrome.
4. Advantages and disadvantages
Ocriplasmin is a recombinant truncated human plasmin (plasmin) drug with the following advantages and disadvantages in clinical application: Advantages: (1) Non-surgical treatment: Ocriplasmin is injected into the eye. Compared with traditional surgical treatment, Ocriplasmin does not need to open the eye, which can reduce the risk and trauma of surgery. (2) Quick treatment: Ocriplasmin can solve problems such as retinal macular and vitreous adhesion in a short time, and see quick results. (3) Personalized treatment: The dosage and treatment of Ocriplasmin can be customized according to the specific situation of the patient, enabling personalized treatment. Disadvantages: (1) Not suitable for all patients: Ocriplasmin is not available for all patients with macular lysis syndrome and periretinal adhesiveness and requires a thorough evaluation and individualized treatment plan by a physician. (2) Uncertain efficacy: The efficacy of Ocriplasmin is not guaranteed in all patients, and some patients may need repeated treatment or other treatments to get the best results. (3) May lead to side effects: The use of Ocriplasmin may also cause some adverse reactions, such as blurred vision, eye pain, eye inflammation, etc., which requires close monitoring and adjustment of a treatment plan. In general, Ocriplasmin as a non-surgical treatment of macular lysis syndrome and periretinal adhesion, has certain advantages and limitations, in the specific use of the patient's individual condition and the risk and benefit of drug use needs to be considered in a comprehensive evaluation.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.